

Correction: Increased Frequency of ICOS⁺ CD4⁺ T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy

In this article (*Cancer Immunol Res* 2013;1:229–34), which was published in the October 2013 issue of *Cancer Immunology Research* (1), the grant support is listed incorrectly. It should read as follows: "The work of P. Sharma, J.D. Wolchok, and J.P. Allison is supported by a Stand Up To Cancer – Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research." The publisher regrets this error.

Reference

1. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, et al. Increased frequency of ICOS⁺ CD4⁺ T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. *Cancer Immunol Res* 2013;1:229–34.

Published OnlineFirst April 4, 2014.

doi: 10.1158/2326-6066.CIR-14-0056

©2014 American Association for Cancer Research.